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EDITORIAL

The Risk is Small: Implant Complications of Leadless
Pacemakers are Related to Body Size
Chu-Pak Lau*
Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China

L

eadless cardiac pacemakers (LPM) are
increasingly used for permanent pacing.
Compared to transvenous pacemakers (TVP) with
conventional pacing leads, LPM have been shown to
provide effective ventricular demand pacing (VVI)
with or without rate adaptation (VVIR). LPM avoid
the acute and long-term risks related to the leads
and pacemaker pockets [1]. Efﬁcacy and electrical
performance is comparable to TVP. However,
implant complications remained signiﬁcant, especially life-threatening pericardial effusion and tamponade. In carefully conducted clinical studies such
as the Investigational Device Exemption (IDE) study
[2] and post approval registry (PAR) [3], pericardial
tamponade/effusion occurred in 1.79% and 0.77%
respectively. A recent report [4] found that LPM to
be increasingly used in older patients between 2017
and 2019 in the United States of America compared
to TVP, the implant complication rate was lower
(8.6% vs 11.2%), but mortality was higher (5.2% vs
1.3%, p < 0.001), driven mainly by pericardial effusion/tamponade.
In this issue of the Journal of Hong Kong College
of Cardiology, Tam et al. [5] addressed the safety
and efﬁcacy of LPM in 147 patients implanted in a
territory referral center between 2015 and 2018.
Their cohort was 80.5 ± 8.7 years old, with high
prevalence of co-morbidities (except for chronic
lung disease), as expected for this age group who
required permanent pacing. Their procedural efﬁcacy and safety were 95.2% and 97.3%, respectively.
These results compared well to those published by
IDE study [2] and the PAR [3], and testify to the
proﬁciency of their centre. Nevertheless, pericardial

tamponade/effusion remained a signiﬁcant issue
(2%), most of them requiring pericardial drainage.
Based on the clinical characteristics of their
cohort, the authors identiﬁed only small body mass
index (BMI) to be signiﬁcantly related to failure to
achieve successful composite efﬁcacy and safety
outcome on univariate risk prediction (BMI 22.12 vs
23.86 kg/m2, p ¼ 0.001; body weight 53.18 ± 5.66 vs
59.15 ± 11.33 kg, p ¼ 0.07). In a secondary analysis
based on the median body weight, the BMI group
that was below the median had more implants at
mid- or high septal region of the right ventricle
(RV), implant attempts, need for recapture and
longer procedure time compared to those above
median weight. Need for more implantation attempts obviously increased the risk of trauma to the
RV and perforation. A small BMI was most likely
associated with a smaller RV size and increased the
risk. An international series [6] identiﬁed 32/2817
patients (1.1%) with pericardial effusion/tamponade
after LPM, and they also found univariate predictors
for this complication to be related to small BMI
(25.7 ± 6 vs 27.8 ± 5.7 kg/m2), in addition to
advanced age (85 yrs), chronic lung disease, and a
history of atrial ﬁbrillation. Small BMI that was
signiﬁcantly related to this complications occurred
in those with 25.7 ± 6.0 kg/m2, and the risk was 4
times higher for BMI below 20 kg/m2.
What are the implications of these ﬁndings? While
risk factors for pericardial effusion/tamponade may
differ from the patient demographics and difference
in implant technique, a common denominator for
complications in these different international cohorts appeared to be due to small body build. While
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it remained to be tested, small body build in these
series probably translated to smaller RV size and
increased the risk of perforations. Whether a
smaller RV also increased repositioning rate and a
higher ﬁnal implant position remained possibility to
be tested. As the standard 27F delivery sheath for
Micra™ (Medtronic Inc) and the same LPM were
used for all patients, appropriate sizing and
improvement in delivery strategy/equipment may
be warranted. At present, caution and preparation
for pericardial effusion therapy are warranted to
address this issue, particularly in those with low
body weight.
The study results should be taken with some
limitations. Being a cohort study, there was no
control on the implant protocol and follow up may
not be uniform. As the study spanned over a 3 year
period, experience and knowledge of the relevant
site of RV pacing to avoid complications such as the
mid-septal RV would be useful to see a time related
trend [7]. A measurement of RV size such as using
echocardiography would be helpful rather than a
crude BMI measurement.
In summary, implantation of LPM can be achieved in a high percentage of patients and LPM are
safe and effective. Implant risks were small, but a
small body weight was riskier.
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